Disintegrin variants and pharmaceutical uses thereof

Woei-Jer Chuang (Inventor)

Research output: Patent

Abstract

Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.
Original languageEnglish
Patent number598176
Publication statusPublished - 2012 Mar 30

Fingerprint

Disintegrins
Integrins
Pharmaceutical Preparations
Peptides

Cite this

@misc{d1185141b93c4f75896debd12fd1de17,
title = "Disintegrin variants and pharmaceutical uses thereof",
abstract = "Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.",
author = "Woei-Jer Chuang",
year = "2012",
month = "3",
day = "30",
language = "English",
type = "Patent",
note = "598176",

}

TY - PAT

T1 - Disintegrin variants and pharmaceutical uses thereof

AU - Chuang, Woei-Jer

PY - 2012/3/30

Y1 - 2012/3/30

N2 - Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.

AB - Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.

M3 - Patent

M1 - 598176

ER -